Moderna said the submission is based on the FDA’s recommendation that vaccine makers update their jabs to target omicron subvariant XBB.1.5.
Moderna said the submission is based on the FDA’s recommendation that vaccine makers update their jabs to target omicron subvariant XBB.1.5.